
SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. (SWTX) Cash on Hand — Cash & Short-Term Investments
Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.
SWTX · cash on hand · updated Dec 31, 2024
Core cash position
as of Dec 31, 2024Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.
Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD
Net cash vs debt
Cash vs Debt · Balance Sheet HealthSpringWorks Therapeutics, Inc. has a net cash position of $300.1M, holding more cash than debt.
Cash on hand history
Annual cash on hand by year
SWTX cash & short-term investments historyHealthcare Sector Cash Reserves Comparison
About cash on hand & methodology
SpringWorks Therapeutics, Inc. (SWTX) cash on hand as of December 31, 2024 is $308.0M, comprising $69.8M in cash and cash equivalents (CCE) plus $238.2M in short-term investments — reported as SpringWorks Therapeutics, Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as SpringWorks Therapeutics, Inc. cash reserves or cash position.
SpringWorks Therapeutics, Inc. annual cash on hand history shows decreased -35.7% in 2024: decreased -35.7% in 2024. SpringWorks Therapeutics, Inc. cash reserves in 2024 reflect the company's capital allocation strategy.
SpringWorks Therapeutics, Inc. carries total debt of $7.9M against cash of $308.0M, resulting in a net cash position of +$300.1M. For the full balance sheet, see the Financials → Balance Sheet tab.
Frequently asked questions
SWTX cash on hand · 5 questionsAs of December 31, 2024, SpringWorks Therapeutics, Inc. (SWTX) has $307,985,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $69,751,000 in cash and cash equivalents (CCE) plus $238,234,000 in short-term investments. Latest quarter (March 31, 2025): $287,873,000. Data sourced from the annual 10-K filing via FMP.
▸ Source: FMP /balance-sheet-statement · US GAAP · SpringWorks Therapeutics, Inc. · SpringWorks Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2024